Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.

摘要: EST 5275 is a phase II and III study of fluorouracil plus streptozocin (5-FU STZ) or doxorubicin in patients with measurable progressive carcinoid tumor. Among one hundred seventy-two cases no prior chemotherapy heart disease, the response rate was 22% for 5-FU STZ 21% doxorubicin, while median duration survival were 31 weeks 64 combination 26 48 doxorubicin. Thirty-three who failed crossed over to achieved an 18% response. Of thirty-five on 29% responded STZ. Hematologic toxicity similar both treatments; however, experienced more vomiting but acceptable renal toxicity. Both regimens have antitumor activity tumors.